Sohrab Shah, PhD

Chief of Computational Oncology; Nicholls-Biondi Chair in Computational Oncology
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Sohrab Shah, PhD

Chief of Computational Oncology; Nicholls-Biondi Chair in Computational Oncology
Share
Share
Sohrab Shah

Office Phone

646-608-7558

Email

[email protected]

URL

View Sohrab Shah’s Lab

Dr. Shah is the Chief of Computational Oncology in the Department of Epidemiology and Biostatistics. His laboratory studies tumor evolution - primarily in genomically unstable cancers.  This encompasses uncovering the root causes of tumor initiation, drug resistance and metastasis through single cell approaches, computational modeling and the theoretical principles of evolution. His lab has pioneered computational methods and single cell technologies to enable advances in understanding drug resistance, immune selective pressures and mutational processes - primarily in breast and ovarian cancer. In addition, since joining MSK he has led a new program in analyzing real-world data from patients including clinical genomics, digital pathology and radiology with AI and machine learning methods to develop predictive models for personalized medicine. Dr. Shah is a former Canada Research Chair, is a Susan G. Komen Scholar, and holds the Nicholls-Biondi Chair in Computational Oncology at MSK.

Publications

Ovarian cancer mutational processes drive site-specific immune evasion. Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP. Nature. 2022 Dec;612(7941):778-786.. Epub 2022 Dec 14. PMID: 36517593; PMCID: PMC9771812.

Single-cell genomic variation induced by mutational processes in cancer. Funnell T, O’Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, Vázquez-García I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, Zhang AW, Lim JLP, Wang B, Brimhall J, Biele J, Ting J, Au V, Van Vliet M, Liu YF, Beatty S, Lai D, Pham J, Grewal D, Abrams D, Havasov E, Leung S, Bojilova V, Moore RA, Rusk N, Uhlitz F, Ceglia N, Weiner AC, Zaikova E, Douglas JM, Zamarin D, Weigelt B, Kim SH, Da Cruz Paula A, Reis-Filho JS, Martin SD, Li Y, Xu H, de Algara TR, Lee SR, Llanos VC, Huntsman DG, McAlpine JN; IMAXT Consortium; Shah SP, Aparicio S. Nature. 2022 Dec;612(7938):106-115. Epub 2022 Oct 26. PMID: 36289342; PMCID: PMC9712114.

Multimodal integration of radiology, pathology, and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Vanguri RS, Luo J, Aukerman AT, Egger JV, Fong CJ, Horvat N, Pagano A, Araujo-Filho JAB, Geneslaw L, Rizvi H, Sosa R, Boehm KM, Yang SR, Bodd FM, Ventura K, Hollmann TJ, Ginsberg MS, Gao J; MSK MIND Consortium; Hellmann MD, Sauter JL, Shah SP. Nat Cancer. 2022 Oct;3(10):1151-1164.Epub 2022 Aug 29. PMID: 36038778; PMCID: PMC9586871.

Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Boehm KM, Aherne EA, Ellenson L, Nikolovski I, Alghamdi M, Vázquez-García I, Zamarin D, Long Roche K, Liu Y, Patel D, Aukerman A, Pasha A, Rose D, Selenica P, Causa Andrieu PI, Fong C, Capanu M, Reis-Filho JS, Vanguri R, Veeraraghavan H, Gangai N, Sosa R, Leung S, McPherson A, Gao J; MSK MIND Consortium; Lakhman Y, Shah SP. Nat Cancer. 2022 Jun;3(6):723-733. Epub 2022 Jun 28. PMID: 35764743; PMCID: PMC9239907.

Clonal fitness inferred from time-series modelling of single-cell cancer genomes. Salehi S, Kabeer F, Ceglia N, Andronescu M, Williams MJ, Campbell KR, Masud T, Wang B, Biele J, Brimhall J, Gee D, Lee H, Ting J, Zhang AW, Tran H, O’Flanagan C, Dorri F, Rusk N, de Algara TR, Lee SR, Cheng BYC, Eirew P, Kono T, Pham J, Grewal D, Lai D, Moore R, Mungall AJ, Marra MA; IMAXT Consortium; McPherson A, Bouchard-Côté A, Aparicio S, Shah SP. Nature. 2021 Jul;595(7868):585-590. Epub 2021 Jun 23. PMID: 34163070; PMCID: PMC8396073.

Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector. Ceglia N, Sethna Z, Freeman SS, Uhlitz F, Bojilova V, Rusk N, Burman B, Chow A, Salehi S, Kabeer F, Aparicio S, Greenbaum BD, Shah SP, McPherson A. Nat Commun. 2023 Jul 20;14(1):4400 PMID: 37474509; PMCID: PMC10359421.

Harnessing multimodal data integration to advance precision oncology. Boehm KM, Khosravi P, Vanguri R, Gao J, Shah SP. Nat Rev Cancer. 2022 Feb;22(2):114-126. Epub 2021 Oct 18. PMID: 34663944; PMCID: PMC8810682.

Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing. Laks E, McPherson A, Zahn H, Lai D, Steif A, Brimhall J, Biele J, Wang B, Masud T, Ting J, Grewal D, Nielsen C, Leung S, Bojilova V, Smith M, Golovko O, Poon S, Eirew P, Kabeer F, Ruiz de Algara T, Lee SR, Taghiyar MJ, Huebner C, Ngo J, Chan T, Vatrt-Watts S, Walters P, Abrar N, Chan S, Wiens M, Martin L, Scott RW, Underhill TM, Chavez E, Steidl C, Da Costa D, Ma Y, Coope RJN, Corbett R, Pleasance S, Moore R, Mungall AJ, Mar C, Cafferty F, Gelmon K, Chia S; CRUK IMAXT Grand Challenge Team; Marra MA, Hansen C, Shah SP, Aparicio S. Cell. 2019 Nov 14;179(5):1207-1221.e22. PMID: 31730858; PMCID: PMC6912164.

Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling. Zhang AW, O’Flanagan C, Chavez EA, Lim JLP, Ceglia N, McPherson A, Wiens M, Walters P, Chan T, Hewitson B, Lai D, Mottok A, Sarkozy C, Chong L, Aoki T, Wang X, Weng AP, McAlpine JN, Aparicio S, Steidl C, Campbell KR, Shah SP. Nat Methods. 2019 Oct;16(10):1007-1015. Epub 2019 Sep 9. PMID: 31501550; PMCID: PMC7485597.

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP. Cell. 2018 Jun 14;173(7):1755-1769.e22. Epub 2018 May 10. PMID: 29754820.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP. Nat Genet. 2017 Jun;49(6):856-865. Epub 2017 Apr 24. PMID: 28436987.

Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice LM, Khattra J, Smith MA, Nielsen CB, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall AJ, Marra MA, Bouchard-Côté A, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. Nat Genet. 2016 Jul;48(7):758-67. Epub 2016 May 16. PMID: 27182968.

The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. Nature. 2012 Apr 4;486(7403):395-9. PMID: 22495314; PMCID: PMC3863681.

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group; Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S. Nature. 2012 Apr 18;486(7403):346-52. PMID: 22522925; PMCID: PMC3440846.

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. Nature. 2009 Oct 8;461(7265):809-13.PMID: 19812674. 

View a complete listing of Sohrab Shah’s publications

My Pages

My Videos

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sohrab Shah discloses the following relationships and financial interests:

  • AstraZeneca UK Limited
    Professional Services and Activities (Uncompensated)
  • Bristol-Myers Squibb
    Professional Services and Activities (Uncompensated)
  • Imagia Canexia Health Inc.
    Equity

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures
Related topics: